130 related articles for article (PubMed ID: 37184432)
1. Effect of HER2-targeted therapy on PDX and PDX-derived organoids generated from HER2-positive salivary duct carcinoma.
Aoyama J; Nojima Y; Sano D; Hirai Y; Kijima N; Aizawa Y; Takada K; Hatano T; Takahashi H; Nishimura G; Oridate N
Head Neck; 2023 Jul; 45(7):1801-1811. PubMed ID: 37184432
[TBL] [Abstract][Full Text] [Related]
2. Establishment of experimental salivary gland cancer models using organoid culture and patient-derived xenografting.
Aizawa Y; Takada K; Aoyama J; Sano D; Yamanaka S; Seki M; Kuze Y; Ramilowski JA; Okuda R; Ueno Y; Nojima Y; Inayama Y; Hatakeyama H; Hatano T; Takahashi H; Nishimura G; Fujii S; Suzuki Y; Taniguchi H; Oridate N
Cell Oncol (Dordr); 2023 Apr; 46(2):409-421. PubMed ID: 36538240
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
[TBL] [Abstract][Full Text] [Related]
4. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
[TBL] [Abstract][Full Text] [Related]
5. The implications of TrkA and MET aberrations in de novo salivary duct carcinoma.
Ryu HJ; Koh YW; Yoon SO
Hum Pathol; 2018 Nov; 81():18-25. PubMed ID: 29753009
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
Masubuchi T; Tada Y; Maruya S; Osamura Y; Kamata SE; Miura K; Fushimi C; Takahashi H; Kawakita D; Kishimoto S; Nagao T
Int J Clin Oncol; 2015 Feb; 20(1):35-44. PubMed ID: 24553861
[TBL] [Abstract][Full Text] [Related]
8. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
[TBL] [Abstract][Full Text] [Related]
9. HER2/HER3-positive metastatic salivary duct carcinoma in the pleural effusion: A case report.
Murata K; Kawahara A; Ono T; Takase Y; Abe H; Naito Y; Akiba J
Diagn Cytopathol; 2018 May; 46(5):429-433. PubMed ID: 29205961
[TBL] [Abstract][Full Text] [Related]
10. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
Falchook GS; Lippman SM; Bastida CC; Kurzrock R
Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA Profiling of Salivary Duct Carcinoma Versus Her2/Neu Overexpressing Breast Carcinoma Identify miR-10a as a Putative Breast Related Oncogene.
Balatti V; Oghumu S; Bottoni A; Maharry K; Cascione L; Fadda P; Parwani A; Croce C; Iwenofu OH
Head Neck Pathol; 2019 Sep; 13(3):344-354. PubMed ID: 30259272
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma.
Kondo Y; Kikuchi T; Esteban JC; Kumaki N; Ogura G; Inomoto C; Hirabayashi K; Kajiwara H; Sakai A; Sugimoto R; Otsuru M; Okami K; Tsukinoki K; Nakamura N
Pathol Int; 2014 Sep; 64(9):453-9. PubMed ID: 25209856
[TBL] [Abstract][Full Text] [Related]
13. The significance of tyrosine kinase receptor B and brain-derived neurotrophic factor expression in salivary duct carcinoma.
Kondo Y; Hirabayashi K; Carreras J; Tsukinoki K; Ota Y; Okami K; Nakamura N
Ann Diagn Pathol; 2021 Feb; 50():151673. PubMed ID: 33248386
[TBL] [Abstract][Full Text] [Related]
14. Establishment of PDX-derived salivary adenoid cystic carcinoma cell lines using organoid culture method.
Takada K; Aizawa Y; Sano D; Okuda R; Sekine K; Ueno Y; Yamanaka S; Aoyama J; Sato K; Kuwahara T; Hatano T; Takahashi H; Arai Y; Nishimura G; Taniguchi H; Oridate N
Int J Cancer; 2021 Jan; 148(1):193-202. PubMed ID: 32984947
[TBL] [Abstract][Full Text] [Related]
15. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.
Wang K; Russell JS; McDermott JD; Elvin JA; Khaira D; Johnson A; Jennings TA; Ali SM; Murray M; Marshall C; Oldham DS; Washburn D; Wong SJ; Chmielecki J; Yelensky R; Lipson D; Miller VA; Stephens PJ; Serracino HS; Ross JS; Bowles DW
Clin Cancer Res; 2016 Dec; 22(24):6061-6068. PubMed ID: 27334835
[TBL] [Abstract][Full Text] [Related]
16. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.
Mitani Y; Rao PH; Maity SN; Lee YC; Ferrarotto R; Post JC; Licitra L; Lippman SM; Kies MS; Weber RS; Caulin C; Lin SH; El-Naggar AK
Clin Cancer Res; 2014 Dec; 20(24):6570-81. PubMed ID: 25316813
[TBL] [Abstract][Full Text] [Related]
17. Primary and Secondary/ Metastatic Salivary Duct Carcinoma Presenting within the Sinonasal Tract.
Agaimy A; Mueller SK; Bishop JA; Chiosea SI
Head Neck Pathol; 2021 Sep; 15(3):769-779. PubMed ID: 33428064
[TBL] [Abstract][Full Text] [Related]
18. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.
Haderlein M; Scherl C; Semrau S; Lettmaier S; Hecht M; Erber R; Iro H; Fietkau R; Agaimy A
Strahlenther Onkol; 2017 Nov; 193(11):961-970. PubMed ID: 28828496
[TBL] [Abstract][Full Text] [Related]
19. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.
Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS
Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517
[TBL] [Abstract][Full Text] [Related]
20. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma.
Jeong JS; Cho KJ; Kim D; Lee YS; Song JS
Pathol Res Pract; 2021 Dec; 228():153678. PubMed ID: 34781210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
